Search results
Results From The WOW.Com Content Network
Gender-affirming hormone therapy (GAHT), also called hormone replacement therapy (HRT) or transgender hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity.
There are certain drugs that increase or decrease the activity of cytochrome P450 enzymes and may cause increased or decreased levels of testosterone: Enzyme inducers – May cause decreased levels of testosterone (and other sex steroid) levels: Phenobarbital and phenytoin (seizure medicines), rifampin (antibiotic), and alcohol.
According to pediatric endocrinology expert Brad Miller, pharmaceutical companies that make puberty blocker drugs for children with gender dysphoria have refused to submit them for FDA approval because doing so would cost too much money and "because (transgender treatment) was a political hot potato." [58]
Gender identity: Gender identity refers to an individual's sense of self as a woman, man, both, neither, somewhere in between, or whatever one's truth is. Gender identity (despite what the gender ...
In addition, visibility of non-cisgender identities is defined by the work environment of the clinic. Front-desk staff and medical assistants will interact with patients, which these guidelines recommend appropriate training. The existence of at least one gender-neutral bathroom shows consideration of patients with non-binary gender identities ...
Gender-biased diagnosing is the idea that medical and psychological diagnosis are influenced by the patient's gender. Several studies have found evidence of differential diagnosis for patients with similar ailments but of different sexes. [ 1 ]
England’s youth gender clinic research also found that medical interventions did not help the mental health of children with gender dysphoria. Puberty blockers are not a Food and Drug ...
For prevention, the WHI suggested that HRT may increase risk of dementia if initiated after 65 years of age, but have a neutral outcome or be neuroprotective for those between 50 and 55 years. [31] Other studies in perimenopause have shown HRT to be consistently associated with a lower risk of Alzheimer's.